New Zealand markets closed

Bausch Health Companies Inc. (BHC)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
10.61+0.12 (+1.14%)
At close: 04:00PM EDT
10.61 0.00 (0.00%)
After hours: 07:47PM EDT

Bausch Health Companies Inc.

2150 St. ElzEar Boulevard West
Laval, QC H7L 4A8
Canada
514 744 6792
https://www.bauschhealth.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees20,270

Key executives

NameTitlePayExercisedYear born
Mr. Thomas J. AppioCEO & Director4.73MN/A1962
Ms. Seana CarsonExecutive VP & General Counsel720.5kN/A1973
Mr. John S. BarresiSenior VP, Controller, Chief Accounting Officer & Interim CFON/AN/A1973
Mr. Mirza DautbegovicSenior VP & COON/AN/AN/A
Mr. Josh CoyleSenior Vice President of Sales & SalixN/AN/AN/A
Ms. Kathleen FitzpatrickSenior VP & Chief HR OfficerN/AN/AN/A
Dr. Tage Ramakrishna M.D.Chief Medical Officer and President of R&DN/AN/A1974
Mr. Jeff HartnessExecutive VP of Market Access, Commercial Operations, Neurology, Generics & Government AffairsN/AN/AN/A
Dr. Graham JacksonSenior VP & Chief Quality OfficerN/AN/AN/A
Mr. Cees HeimanSenior Vice President of Europe & CanadaN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Corporate governance

Bausch Health Companies Inc.’s ISS governance QualityScore as of 1 March 2024 is 4. The pillar scores are Audit: 5; Board: 2; Shareholder rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.